Mandate

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.

The share issue was directed to a number of selected Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson and Lorin Arabi.

Related

Vinge advises Ambea on the acquisition of Validia

Vinge has acted as advisor to Ambea AB (publ) together with the Finnish law firm Krogerus in connection with the acquisition of Validia Oy from Invalidiliitto, the Finnish Association for the Disabled, a leading care provider in Finland. Through the acquisition, Ambea establishes a presence in the Finnish market and strengthens its position as the only care provider with operations in the four largest Nordic countries. The purchase price amounts to a total of SEK 1, 382 million.
March 12, 2025

Vinge has advised Röko in connection with its listing on Nasdaq Stockholm

Vinge has advised Röko AB (publ) (“Röko”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on March 4, 2025 and the first day of trading is March 11, 2025.
March 11, 2025

Vinge has advised Ingrid Capacity in new co-operation with Locus Energy, one of SEB Nordic Energy's portfolio companies

Vinge has advised Ingrid Capacity in connection with a new project together with Locus Energy, a leading Nordic energy infrastructure company owned by SEB Asset Management's SEB Nordic Energy fund, to develop Finland's largest and one of the Nordic region's largest battery storage systems.
March 07, 2025